Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only two descriptive claims are clearly supported by the provided label excerpt (DESCRIPTION). Other substantive formulation/market claims are not supported by cited labeling, and the evaluation does not cover multiple priority label areas (e.g., boxed warnings/contraindications/pregnancy/pediatrics/detailed dosing safety), limiting on-label alignment assurance.
Category Scores
Accurate Statements
Imuran is the brand name for azathioprine.
DESCRIPTION indicates IMURAN (azathioprine).
The chemical name of azathioprine is 6-[(1-methyl-4-nitroimidazol-5-yl)thio]-1H-purine.
DESCRIPTION provides azathioprine chemical name/nomenclature.
Unsupported Statements
Generic versions marketed as azathioprine use the same active ingredient as Imuran.
Not supported by the provided label sections/excerpts; no label citation provided.
Azathioprine tablets may differ by manufacturer and inactive ingredients.
Not supported by the provided label sections/excerpts; no label citation provided.
Azathioprine products are commonly sold in strengths such as 50 mg.
Only the label excerpt specifies Imuran tablets contain 50 mg azathioprine; the claim asserts a broader market-wide/common-strength characterization not supported by provided label text.
Contradictions
Important Omissions
Coverage of boxed warnings, contraindications, and other key safety sections was not addressed in the evaluated content.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
The evaluated response largely contains non-dosing descriptive claims, but it includes unsupported formulation/market generalizations and does not demonstrate label-covered safety content audit coverage (e.g., boxed warnings/contraindications), which reduces confidence in on-label accuracy for patient-facing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple claims are not supported by the provided FDA label excerpts/citations, and key safety-related label areas were not audited.
Suggested Improvement
Restrict claims to what is explicitly supported by cited label sections (e.g., DESCRIPTION for chemical identity and Imuran tablet 50 mg content) and re-audit against additional label sections (contraindications, boxed warnings, pregnancy/lactation, pediatric use, and detailed dosing/administration safety) with precise citations.